AIM ImmunoTech (FRA:HXB) Cyclically Adjusted FCF per Share: €-3,536.17 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HXB AIM ImmunoTech Inc FRA:HXB
33 GF Score
Price €3.61
GF Value €34.97
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Cyclically Adjusted FCF per Share?

AIM ImmunoTech FRA:HXB 33 Cyclically Adjusted FCF per Share is €-3,536.17 as of Mar. 2026. GuruFocus rates FRA:HXB with a GF Score™ of 33/100 and a GF Value™ of €34.97. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

AIM ImmunoTech's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.547. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-3,536.17 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 36.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 28.50% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 20.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of AIM ImmunoTech was 36.10% per year. The lowest was -10.10% per year. And the median was 10.40% per year.

As of today (2026-07-27), AIM ImmunoTech's current stock price is €3.61351. AIM ImmunoTech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-3,536.17. AIM ImmunoTech's Cyclically Adjusted Price-to-FCF of today is .


AIM ImmunoTech  (FRA:HXB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


AIM ImmunoTech Cyclically Adjusted FCF per Share Related Terms


AIM ImmunoTech Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Cyclically Adjusted FCF per Share Chart

AIM ImmunoTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,553.97 -1,201.74 -906.20 -640.12 -1,894.41

AIM ImmunoTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -512.38 -324.63 -905.89 -1,894.41 -3,536.17

FRA:HXB vs NIKI, PMCB, PCSA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, AIM ImmunoTech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Cyclically Adjusted Price-to-FCF falls into.


FRA:HXB
33GF Score
AIM ImmunoTech Inc FRA:HXB
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AIM ImmunoTech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.547/330.2130*330.2130
=-0.547

Current CPI (Mar. 2026) = 330.2130.

AIM ImmunoTech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -276.600 241.018 -378.963
201609 -545.600 241.428 -746.244
201612 -400.800 241.432 -548.185
201703 -468.500 243.801 -634.554
201706 -342.833 244.955 -462.158
201709 -230.000 246.819 -307.711
201712 -93.286 246.524 -124.954
201803 -259.125 249.554 -342.877
201806 -235.100 251.989 -308.081
201809 -236.364 252.439 -309.185
201812 -194.273 251.233 -255.347
201903 -117.583 254.202 -152.742
201906 -134.421 256.143 -173.292
201909 -89.654 256.759 -115.302
201912 -20.635 256.974 -26.516
202003 -17.394 258.115 -22.253
202006 -4.340 257.797 -5.559
202009 -6.532 260.280 -8.287
202012 -6.308 260.474 -7.997
202103 -6.255 264.877 -7.798
202106 -3.023 271.696 -3.674
202109 -6.288 274.310 -7.569
202112 -10.900 278.802 -12.910
202203 -5.279 287.504 -6.063
202206 -4.634 296.311 -5.164
202209 -10.474 296.808 -11.653
202212 -12.254 296.797 -13.634
202303 -7.101 301.836 -7.769
202306 -4.107 305.109 -4.445
202309 -10.912 307.789 -11.707
202312 -18.299 306.746 -19.699
202403 -9.042 312.332 -9.560
202406 -5.684 314.175 -5.974
202409 -5.102 315.301 -5.343
202412 -6.089 315.605 -6.371
202503 -3.181 319.799 -3.285
202506 -2.005 322.561 -2.053
202509 -2.064 324.800 -2.098
202512 -0.578 324.054 -0.589
202603 -0.547 330.213 -0.547

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-3,536.17 mean?
AIM ImmunoTech (FRA:HXB) has a Cyclically Adjusted FCF per Share of €-3,536.17 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on AIM ImmunoTech and its competitors.
Is AIM ImmunoTech's Cyclically Adjusted FCF per Share too high?
AIM ImmunoTech's current Cyclically Adjusted FCF per Share is €-3,536.17. Overall, AIM ImmunoTech has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Cyclically Adjusted FCF per Share compare to NIKI and PMCB?
AIM ImmunoTech's Cyclically Adjusted FCF per Share of €-3,536.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Cyclically Adjusted FCF per Share is €-3,536.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
AIM ImmunoTech (FRA:HXB) has a current Cyclically Adjusted FCF per Share of €-3,536.17. The stock's GF Value™ is €34.97, compared to a current price of €3.61 — trading 89.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-3,536.17. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For AIM ImmunoTech (FRA:HXB), the current Cyclically Adjusted FCF per Share is €-3,536.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (FRA:HXB) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of €3.61 is trading 89.7% below its estimated GF Value™ of €34.97.

Key valuation signals for FRA:HXB:

  • Cyclically Adjusted FCF per Share: €-3,536.17
  • GF Value™: €34.97 vs. price of €3.61 (89.7% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the FRA:HXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AIM ImmunoTech Business Description

Other Exchanges AIM:USA0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for FRA:HXB

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.61
Price
€34.97
GF Value